Santiago Fontes, Medical Oncologist, Immuno-Oncology Specialist, shared a post on LinkedIn:
“A thought-provoking analysis by Teresa Macarulla at ESMO GI 2026 on one of the key questions in pancreatic cancer: how to maximize the impact of RAS inhibition.
The discussion highlighted that success will depend not only on developing effective inhibitors, but also on understanding when to use them, how to overcome resistance, and which rational combinations can deliver more durable benefit.
As the therapeutic landscape evolves, optimizing sequencing and combination strategies will be central to improving outcomes for patients with PDAC.”
Other articles featuring Santiago Fontes on OncoDaily.